-
Company Profile
![]()
Celgene Corp – Company Profile
Celgene Corp (Celgene), a subsidiary of Bristol-Myers Squibb Co, is an integrated biopharmaceutical company that discovers, develops, manufactures, and markets novel gene and protein regulation therapies for the treatment of cancer and immune-inflammatory diseases. Its major product portfolio includes Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma, and Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers, among others. The company sells its products through own sales organizations and distributors in Europe,...
Add to Basket -
Sector Analysis
NewDiffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later...
-
Sector Analysis
Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Report Overview PsA is a chronic immune-mediated arthritis that typically affects the large joints, including those of the lower extremities, the distal joints of the fingers and toes, the back, and the sacroiliac joints of the pelvis. Clinical diagnosis and assessment of PsA involve a combination of patient history, physical examination, laboratory tests, and imaging studies. The goal of diagnosis and assessment is to identify the presence and extent of joint involvement, assess...
-
Company Profile
![]()
Editas Medicine Inc – Company Profile
Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, BlueRock Therapeutics,...
Add to Basket -
Product Insights
ArcherDx Inc Pipeline Insight and Competitive Landscape, 2023
ArcherDx Inc (ArcherDx) is a molecular technology company that develops customized genomic medicine-based solutions for the discovery of various types of cancer, auto-immune, and other genetic diseases. It offers comprehensive next-generation sequencing (NGS) assays that enable the detection of deoxyribonucleic acid (DNA)-based variant and copy-number variation (CNV); sensitive variant from circulating tumor (ct) DNA; ribonucleic acid (RNA)-based fusion, expression and variant; and RNA-based immune repertoire analysis. The company also offers a proprietary bioinformatics platform that employs NGS to combine its...
-
Company Insights
Exscientia Ltd. – Tech Innovator Profile
Exscientia Ltd (Exscientia) is a company that automates the drug discovery and design process, leveraging artificial intelligence (AI) and big data technologies. Its AI-driven platform, Centaur AI, enables researchers to design numerous target specific compounds and pre-assess their potency, and Experiment AI provides successful experimental outcomes. This report provides insights into Exscientia Ltd., including an overview of the company and its product offering, detailed coverage of its business model and operations, information on its funding and partnerships, and biographies of...
-
Sector Analysis
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
Access and explore the following in-depth insights from the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report: Disease epidemiology including - Patient segmentation, staging & progression rates, and Disease incidence/prevalence. Marketed products with a breakdown established versus cell therapies, backed with primary research validated base year forecast Commercial assessment and Forecast by number of patients treated per class and future sales projection based on competitive assessment Launch date assessment with estimated launch dates by class of cell therapy and indication-specific assumptions. Evaluation...
-
Product Insights
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. The Melanoma pipeline market research report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Behcet Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems. The Behcet Disease pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteoporosis Pipeline Drugs Market Overview Osteoporosis signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications. The Osteoporosis pipeline drugs market research report provides an analysis of the Osteoporosis drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type....
-
Product Insights
Psoriasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared-up skin, itchiness, burning sensation, and swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections, and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy. The Psoriasis pipeline market research report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug...
-
Thematic Analysis
![]()
Nanotechnology in Medicine – Thematic Research
A persistent problem in medicine is the lack of ability to specifically target diseased cells and tissues. Drugs are often administered as free compounds. This non-specific mode of delivery relies on the drug molecules to serendipitously reach target cells. Nanomedicine refers to the area of science that combines nanotechnology with drugs or diagnostic molecules to improve the ability to target specific cells or tissues. These materials are produced on a nanoscale level and are safe to introduce into the body....
-
Analyst Opinions
Engineering Microorganisms into Powerful Micromachines: Can Synthetic Biology Foster Bio-Revolution?
Achieving global goals such as mass-scale food production and sustainable low-cost manufacturing methods is the need of the hour. Synthetic Biology (SynBio) is a field of science that has grown over the last two decades to emerge as a mature area in biological engineering with its potential to reduce the costs of biological production methods and improve the global food supply. It also can be crucial to create patient-centric drugs and promote precision medicine for better health outcomes. SynBio is...
-
Sector Analysis
HER2+ Breast Cancer – Global Drug Forecast and Market Analysis to 2030
GlobalData valued the 8MM HER-2 + breast cancer market at $10.4 billion in 2020 and expects the market to increase at a low compound annual growth rate (CAGR) of more than 1%. This growth will be driven by the anticipated launches of five pipeline agents, the expansion of several currently approved agents into earlier lines of therapy, and a collective increase in the diagnosed incident population across the 8MM. Growth will be substantially inhibited by generic and biosimilar erosion following...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 (Event Driven Update)
Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule...
-
Sector Analysis
Pancreatic Cancer – Opportunity Analysis and Forecasts to 2029
Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses. The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX...
-
Sector Analysis
Non-Small Cell Lung Cancer – Global Drug Forecast and Market Analysis to 2029
Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015–2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting....
-
Sector Analysis
Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029
Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...
-
Sector Analysis
Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029
Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.